New Alzheimer’s Drugs

Two Alzheimer’s drugs, donanemab (Kisunla) and lecanemab (Leqembi) appear to hold real promise in slowing the progression of the Alzheimer’s disease. Both drugs are designed for individuals in the early stages of the disease, and work by reducing amyloid plaques (or abnormal protein build-ups in the brain that are linked to the disease.)

Donanemab, a drug administered through IV drip once a month, was reported to lower the risk of Alzheimer’s progression by 27%. Further, most patients reached the treatment’s main goal of clearing up amyloid plaques in about a year and a half, and no new side effects were recorded in addition to those already present.

Next, the lecanemab was tested for administration through under-the-skin injections, as it has already been approved as an IV version. The shot was reported to work just as well in clearing amyloid plaques, keeping Alzheimer’s blood markers stable, and helping people maintain thinking skills and daily activities.

Additionally, the shot version of lecanemab appeared to have fewer side effects and seems to be easier for both patients and caregivers. Studies also find that patients can move from the lecanemab IV to the injection without losing any benefits.

Both IV-versions of the drugs have been approved by the FDA. However, both drugs are only known to work when patients can receive the treatment early and continue the treatment consistently. Questions on how to cover the cost are also complicated, as coverage by Medicare or personal insurance is unclear.